There has been intense interest in nuclear receptor targeting for cancer prevention. With the exception of estrogen antagonism in breast carcinoma there has not been widespread adoption or success of this strategy in clinical cancer prevention. Keith and colleagues have performed a careful study, which utilized the PPARg nuclear receptor agonist, pioglitazone, a common type II diabetes agent, in subjects at risk for lung carcinoma. Although the results are not promising with this strategy, the study provides evidence for feasibility accrual and biomarker strategies that could be utilized to gain additional insight in future trials.
PubMed: MeSH publication types